🇺🇸 FDA
Patent

US 10548953

Factor VIII-XTEN fusions and uses thereof

granted A61KA61K38/00A61K38/37

Quick answer

US patent 10548953 (Factor VIII-XTEN fusions and uses thereof) held by BIOVERATIV THERAPEUTICS INC. expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BIOVERATIV THERAPEUTICS INC.
Grant date
Tue Feb 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K38/00, A61K38/37, A61K48/00, A61K9/0019